Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

Abstract

PURPOSE Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors. EXPERIMENTAL DESIGN Phase I study (NPI-0052-102) evaluated the MTD, pharmacokinetics, and pharmacodynamics of marizomib intravenously on two dosing schedules. RESULTS… (More)
DOI: 10.1158/1078-0432.CCR-15-2616

Topics

5 Figures and Tables

Cite this paper

@article{Harrison2016PhaseIC, title={Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.}, author={Simon J Harrison and Paul N. Mainwaring and Timothy Price and Michael J. Millward and Peeter Padrik and Craig R. Underhill and Paul K Cannell and Steven Reich and Mohit Trikha and Andrew Spencer}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2016}, volume={22 18}, pages={4559-66} }